Search Results - "D'Eramo, Anna"

An unusual case of complicated rhinosinusitis of the sphenoid sinus involving the cavernous sinus and skull base: Endoscopic sinus surgery and medical therapy by Fadda, Gian Luca, D’Eramo, Anna, Gned, Dario, Succo, Giovanni, Galizia, Andrea, Cavallo, Giovanni

“…Isolated sphenoid sinus diseases are generally asymptomatic and relatively uncommon with the potential for serious complications. Patients with this condition…”
Get full text

Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia by Naber, Dieter, Hansen, Karina, Forray, Carlos, Baker, Ross A, Sapin, Christophe, Beillat, Maud, Peters-Strickland, Timothy, Nylander, Anna-Greta, Hertel, Peter, Andersen, Henrik Steen, Eramo, Anna, Loze, Jean-Yves, Potkin, Steven G

“…Abstract Objective To directly compare aripiprazole once-monthly 400 mg (AOM 400) and paliperidone palmitate once-monthly (PP) on the Heinrichs–Carpenter…”
Get full text

A Postsynaptic Density Immediate Early Gene-Based Connectome Analysis of Acute NMDAR Blockade and Reversal Effect of Antipsychotic Administration by Barone, Annarita, De Simone, Giuseppe, Ciccarelli, Mariateresa, Buonaguro, Elisabetta Filomena, Tomasetti, Carmine, Eramo, Anna, Vellucci, Licia, de Bartolomeis, Andrea

“…Although antipsychotics' mechanisms of action have been thoroughly investigated, they have not been fully elucidated at the network level. We tested the…”
Get full text

Correction: Using the Goal Attainment Scale adapted for depression to better understand treatment outcomes in patients with major depressive disorder switching to vortioxetine: a phase 4, single-arm, open-label, multicenter study by McCue, Maggie, Sarkey, Sara, Eramo, Anna, François, Clement, Parikh, Sagar V

“…Abstract Graphical Abstract…”
Get full text

Using the Goal Attainment Scale adapted for depression to better understand treatment outcomes in patients with major depressive disorder switching to vortioxetine: a phase 4, single-arm, open-label, multicenter study by McCue, Maggie, Sarkey, Sara, Eramo, Anna, François, Clement, Parikh, Sagar V

“…Major depressive disorder (MDD) is the leading cause of disability worldwide. Response to pharmacologic treatment is generally evaluated by traditional…”
Get full text

Correction to: Using the Goal Attainment Scale adapted for depression to better understand treatment outcomes in patients with major depressive disorder switching to vortioxetine: a phase 4, single-arm, open-label, multicenter study by McCue, Maggie, Sarkey, Sara, Eramo, Anna, François, Clement, Parikh, Sagar V

Get full text

The Effects of Antipsychotics on the Synaptic Plasticity Gene Homer1a Depend on a Combination of Their Receptor Profile, Dose, Duration of Treatment, and Brain Regions Targeted by Iasevoli, Felice, Buonaguro, Elisabetta Filomena, Avagliano, Camilla, Barone, Annarita, Eramo, Anna, Vellucci, Licia, de Bartolomeis, Andrea

“…Antipsychotic agents modulate key molecules of the postsynaptic density (PSD), including the gene, implicated in dendritic spine architecture. How the…”
Get full text

Isolated Sphenoid Sinus Inflammatory Disease-A Report of 14 Cases by Fadda, Gian-Luca, D'Eramo, Anna, Grosso, Alessandro, Galizia, Andrea, Cavallo, Giovanni

“…Isolated sphenoid sinus inflammatory diseases (ISSIDs) are responsible for about 75% of isolated sphenoid sinus opacifications. Computer tomography (CT) and…”
Get full text

Aripiprazole Once-Monthly 400 mg: Comparison of Pharmacokinetics, Tolerability, and Safety of Deltoid Versus Gluteal Administration by Raoufinia, Arash, Peters-Strickland, Timothy, Nylander, Anna-Greta, Baker, Ross A., Eramo, Anna, Jin, Na, Bricmont, Patricia, Repella, Jennifer, McQuade, Robert D., Hertel, Peter, Larsen, Frank

“…Abstract Background: Two open-label, randomized, parallel-arm studies compared pharmacokinetics, safety, and tolerability of aripiprazole once-monthly 400 mg…”
Get full text

Mobile App to Enhance Patient Activation and Patient-Provider Communication in Major Depressive Disorder Management: Collaborative, Randomized Controlled Pilot Study by McCue, Maggie, Blair, Christopher, Fehnert, Ben, King, James, Cormack, Francesca, Sarkey, Sara, Eramo, Anna, Kabir, Christopher, Khatib, Rasha, Kemp, David

“…Background Enhanced patient-provider engagement can improve patient health outcomes in chronic conditions, including major depressive disorder (MDD). Objective…”
Get full text

Relationship between response to aripiprazole once-monthly and paliperidone palmitate on work readiness and functioning in schizophrenia: A post-hoc analysis of the QUALIFY study by Potkin, Steven G, Loze, Jean-Yves, Forray, Carlos, Baker, Ross A, Sapin, Christophe, Peters-Strickland, Timothy, Beillat, Maud, Nylander, Anna-Greta, Hertel, Peter, Nitschky Schmidt, Simon, Ettrup, Anders, Eramo, Anna, Hansen, Karina, Naber, Dieter

“…Schizophrenia is a chronic disease with negative impact on patients' employment status and quality of life. This post-hoc analysis uses data from the QUALIFY…”
Get full text

Hospitalization rates in patients switched from oral anti-psychotics to aripiprazole once-monthly: final efficacy analysis by Kane, John M, Zhao, Cathy, Johnson, Brian R, Baker, Ross A, Eramo, Anna, McQuade, Robert D, Duca, Anna R, Sanchez, Raymond, Peters-Strickland, Timothy

“…To compare hospitalization rates in patients with schizophrenia treated prospectively with aripiprazole once-monthly 400 mg (AOM 400; an extended-release…”
Get more information

Adapting the Goal Attainment Approach for Major Depressive Disorder by McCue, Maggie, Parikh, Sagar V., Mucha, Lisa, Sarkey, Sara, Cao, Charlie, Eramo, Anna, Opler, Mark, Webber-Lind, Briana, François, Clément

“…The need for patient-centered care has become a focal point of healthcare improvement initiatives. Shared decision making—in which patients and clinicians…”
Get full text

Pharmacoeconomic comparison of aripiprazole once-monthly and paliperidone palmitate from a head-to-head clinical trial in schizophrenia: a US analysis by Sapin, Christophe, Hartry, Ann, Kamat, Siddhesh A, Beillat, Maud, Baker, Ross A, Eramo, Anna

“…Schizophrenia presents a substantial clinical and economic burden to the health-care system. In QUAlity of LIfe with AbiliFY Maintena (QUALIFY), a randomized…”
Get full text

Reduction in inpatient resource utilization and costs associated with long-acting injectable antipsychotics across different age groups of Medicaid-insured schizophrenia patients by Kamat, Siddhesh A, Offord, Steve, Docherty, John, Lin, Jay, Eramo, Anna, Baker, Ross A, Gutierrez, Benjamin, Karson, Craig

“…Evaluate utilization of inpatient healthcare resources and associated costs after 12 months of treatment using long-acting injectable (LAI) antipsychotic…”
Get full text

Inpatient resource use and costs associated with switching from oral antipsychotics to aripiprazole once-monthly for the treatment of schizophrenia by Wilson, Michele, Gutierrez, Benjamin, Offord, Steve J, Blanchette, Christopher M, Eramo, Anna, Earnshaw, Stephanie, Kamat, Siddhesh A

“…Schizophrenia is associated with high direct healthcare costs due to progression of disease and frequent occurrence of relapses. Aripiprazole once-monthly…”
Get full text

The Role of Norepinephrine and Its α-Adrenergic Receptors in the Pathophysiology and Treatment of Major Depressive Disorder and Schizophrenia: A Systematic Review by Maletic, Vladimir, Eramo, Anna, Gwin, Keva, Offord, Steve J, Duffy, Ruth A

“…Norepinephrine (NE) is recognized as having a key role in the pathophysiology of major depressive disorder (MDD) and schizophrenia, although its distinct…”
Get full text

Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study by Fleischhacker, W. Wolfgang, Sanchez, Raymond, Perry, Pamela P., Jin, Na, Peters-Strickland, Timothy, Johnson, Brian R., Baker, Ross A., Eramo, Anna, McQuade, Robert D., Carson, William H., Walling, David, Kane, John M.

“…Long-acting injectable formulations of antipsychotics are treatment alternatives to oral agents. To assess the efficacy of aripiprazole once-monthly compared…”
Get full text

PET clinical study of novel antipsychotic LB-102 demonstrates unexpectedly prolonged dopamine receptor target engagement by Wong, Dean F, Chand, Ganesh B, Caito, Nicole, Eramo, Anna, Grattan, Vincent T, Hixon, Mark S, Nicol, Ginger, Lessie, Erin, Prensky, Zachary, Kuwabara, Hiroto, Tian, Lucy, Valenta, Ines, Schindler, Thomas H, Gründer, Gerhard, Vaino, Andrew R

“…Regulation of dopamine activity has important clinical consequences, most notably in schizophrenia. LB-102, N-methyl amisulpride, is a novel dopamine D /5-HT…”
Get full text

Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study by Kane, John M, Peters-Strickland, Timothy, Baker, Ross A, Hertel, Peter, Eramo, Anna, Jin, Na, Perry, Pamela P, Gara, Michelle, McQuade, Robert D, Carson, William H, Sanchez, Raymond

“…To evaluate aripiprazole once-monthly (AOM), a long-acting injectable suspension of aripiprazole, as acute treatment in patients with schizophrenia…”
Get full text